Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510913 · ClinicalTrials.gov registry record · Phase 4
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 450
- Enrollment target
NCT00510913: Completed Phase 4 study, sponsored by Astellas Pharma.
NCT00510913 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 450 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00510913, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 450 participants
- Enrollment target
Study Summary
A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
Interventions
- DRUG tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 1999-02 |
| Est. Completion | 2000-09 |
| Phase | Phase 4 |
What the finished NCT00510913 record still lists
NCT00510913 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 1 intervention - of which tacrolimus is the first listed.
NCT00510913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00510913 about?
NCT00510913 is a clinical study titled "A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure". A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
What is the current status of trial NCT00510913?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 450 participants. The study started on 1999-02. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00510913?
The interventions under investigation include: tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00510913?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00510913's enrollment target sits among peer trials
450 187th of 2000 higher than 1,813 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia